Published in Liver Transpl on December 01, 2002
Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis. Hepatology (2014) 4.01
Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol (2008) 3.23
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol (2013) 2.92
Nonalcoholic fatty liver disease. CMAJ (2005) 2.56
Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia (2009) 2.03
Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology (2013) 1.88
Non-alcoholic fatty liver disease. BMJ (2014) 1.73
Non-invasive means of measuring hepatic fat content. World J Gastroenterol (2008) 1.60
The genetics of NAFLD. Nat Rev Gastroenterol Hepatol (2013) 1.55
What about non-alcoholic fatty liver disease as a new criterion to define metabolic syndrome? World J Gastroenterol (2013) 1.49
Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care (2011) 1.46
Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res (2011) 1.42
Outcomes of donor evaluation in adult-to-adult living donor liver transplantation. Hepatology (2007) 1.31
Diagnosis of hepatic steatosis and fibrosis by transient elastography in asymptomatic healthy individuals: a prospective study of living related potential liver donors. J Gastroenterol (2007) 1.17
Normal controlled attenuation parameter values: a prospective study of healthy subjects undergoing health checkups and liver donors in Korea. Dig Dis Sci (2014) 1.16
Non-alcoholic fatty liver disease: The diagnosis and management. World J Hepatol (2015) 1.11
KASL clinical practice guidelines: management of nonalcoholic fatty liver disease. Clin Mol Hepatol (2013) 1.08
Can NASH be diagnosed, graded, and staged noninvasively? Clin Liver Dis (2012) 1.05
Silymarin in non alcoholic fatty liver disease. World J Hepatol (2013) 1.03
Non-alcoholic fatty liver disease: what the clinician needs to know. World J Gastroenterol (2014) 1.02
Pediatric nonalcoholic fatty liver disease: A clinical and laboratory challenge. World J Hepatol (2010) 1.01
Noninvasive investigations for non alcoholic fatty liver disease and liver fibrosis. World J Gastroenterol (2010) 1.01
Body mass index and adverse perioperative outcomes following hepatic resection. J Gastrointest Surg (2010) 0.98
Nonalcoholic fatty liver disease: Noninvasive methods of diagnosing hepatic steatosis. Saudi J Gastroenterol (2015) 0.95
Clinical review of nonalcoholic steatohepatitis in liver surgery and transplantation. J Am Coll Surg (2010) 0.90
Imaging evaluation of the liver using multi-detector row computed tomography in micropigs as potential living liver donors. J Vet Sci (2009) 0.89
Noninvasive imaging assessment of non-alcoholic fatty liver disease: focus on liver scintigraphy. World J Gastroenterol (2015) 0.88
Non-invasive score identifies ultrasonography-diagnosed non-alcoholic fatty liver disease and predicts mortality in the USA. BMC Med (2014) 0.84
Helicobacter pylori infection is not associated with fatty liver disease including non-alcoholic fatty liver disease: a large-scale cross-sectional study in Japan. BMC Gastroenterol (2015) 0.82
Definitions of Normal Liver Fat and the Association of Insulin Sensitivity with Acquired and Genetic NAFLD-A Systematic Review. Int J Mol Sci (2016) 0.81
Donor selection for adult-to-adult living donor liver transplantation: well begun is half done. Transplantation (2013) 0.79
Hepatic angiogenesis and fibrosis are common features in morbidly obese patients. Hepatol Int (2011) 0.79
Pre-and-post transplant considerations in patients with nonalcoholic fatty liver disease. World J Transplant (2014) 0.78
S-nitroso-N-acetylcysteine ameliorates ischemia-reperfusion injury in the steatotic liver. Clinics (Sao Paulo) (2010) 0.78
Liver biopsy in living donors. Liver Transpl (2002) 0.78
Non-Alcoholic Fatty Liver Disease, a Marker of Subclinical Atherosclerosis Applicable Only to Metabolic Syndrome?: Time to Organize the Connection between Metabolism and Atherosclerosis. J Cardiovasc Ultrasound (2012) 0.77
Noninvasive Prediction of Erosive Esophagitis Using a Controlled Attenuation Parameter (CAP)-Based Risk Estimation Model. Dig Dis Sci (2015) 0.76
From NAFLD to Cardiovascular Disease. Is it (Still) the Metabolic Syndrome? Clujul Med (2014) 0.76
Transient elastography (FibroScan(®)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand? World J Gastroenterol (2016) 0.76
Living donor liver transplantation: eliminating the wait for death in end-stage liver disease? Nat Rev Gastroenterol Hepatol (2017) 0.75
Hepatic steatosis and fibrosis: Non-invasive assessment. World J Gastroenterol (2016) 0.75
Diagnostic accuracy and clinical utility of a new noninvasive index for hepatic steatosis in patients with hepatitis B virus infection. Sci Rep (2016) 0.75
Phosphorylated IGFBP-1 as a non-invasive predictor of liver fat in NAFLD. Sci Rep (2016) 0.75
The triglyceride and glucose index (TyG) is an effective biomarker to identify nonalcoholic fatty liver disease. Lipids Health Dis (2017) 0.75
Assessment of liver fat in an obese patient population using noncontrast CT fat percent index. Clin Imaging (2014) 0.75
Tolerogenic immunosuppression for organ transplantation. Lancet (2003) 4.09
The impact of postreperfusion syndrome on short-term patient and liver allograft outcome in patients undergoing orthotopic liver transplantation. Liver Transpl (2008) 2.11
Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath. J Am Coll Surg (2005) 1.93
Successful treatment of small-for-size syndrome in adult-to-adult living-related liver transplantation: single center series. Clin Transplant (2007) 1.70
Alemtuzumab preconditioning with tacrolimus monotherapy-the impact of serial monitoring for donor-specific antibody. Transplantation (2008) 1.62
Immunosuppression for liver transplantation in HCV-infected patients: mechanism-based principles. Liver Transpl (2005) 1.61
Hypophosphatemia after 95 right-lobe living-donor hepatectomies for liver transplantation is not a significant source of morbidity. Transplantation (2003) 1.57
Kidney transplantation under a tolerogenic regimen of recipient pretreatment and low-dose postoperative immunosuppression with subsequent weaning. Ann Surg (2003) 1.52
Transplantation of en bloc pediatric kidneys when the proximal vascular cuff is too short. Transplantation (2007) 1.42
Antilymphoid antibody preconditioning and tacrolimus monotherapy for pediatric kidney transplantation. J Pediatr (2006) 1.36
MELD and prediction of post-liver transplantation survival. Liver Transpl (2006) 1.33
Adult living donor versus deceased donor liver transplantation: a 6-year single center experience. Am J Transplant (2005) 1.31
Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology (2006) 1.24
Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis (2006) 1.23
Porcine partial liver transplantation: a novel model of the "small-for-size" liver graft. Liver Transpl (2004) 1.22
Pregnancy after liver transplantation with tacrolimus immunosuppression: a single center's experience update at 13 years. Transplantation (2003) 1.18
Pathophysiologic observations and histopathologic recognition of the portal hyperperfusion or small-for-size syndrome. Am J Surg Pathol (2006) 1.12
Liver biopsy findings from healthy potential living liver donors: reasons for disqualification, silent diseases and correlation with liver injury tests. J Hepatol (2008) 1.08
Budd-Chiari syndrome: in evolution. Eur J Gastroenterol Hepatol (2005) 1.05
Analysis of surgical and perioperative complications in seventy-five right hepatectomies for living donor liver transplantation. World J Gastroenterol (2008) 1.04
Ex situ resection techniques and liver autotransplantation: last resource for otherwise unresectable malignancy. Dig Dis Sci (2005) 1.01
Persistent donor-specific alloreactivity may portend delayed liver rejection during drug minimization in children. Front Biosci (2007) 0.98
Pregnancy after kidney and kidney-pancreas transplantation under tacrolimus: a single center's experience. Transplantation (2004) 0.97
Diagnosis and treatment of intracardiac thrombosis during orthotopic liver transplantation. Anesth Analg (2004) 0.94
Lessons of organ-induced tolerance learned from historical clinical experience. Transplantation (2004) 0.94
Caroli's disease and orthotopic liver transplantation. Liver Transpl (2006) 0.92
Clinical tolerance following liver transplantation: long term results and future prospects. Transpl Immunol (2006) 0.91
Living-related donor renal transplantation in HIV+ recipients using alemtuzumab preconditioning and steroid-free tacrolimus monotherapy: a single center preliminary experience. Transplantation (2004) 0.91
Significance of the effective remnant liver volume in major hepatectomies. Am Surg (2005) 0.89
Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: long-term experience from a single center. Transplantation (2005) 0.89
Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients. Liver Transpl (2003) 0.88
Long-term outcome of adding mycophenolate mofetil to tacrolimus for nephrotoxicity following liver transplantation. Transplantation (2005) 0.87
Wound healing in the biliary tree of liver allografts. Cell Transplant (2006) 0.86
Adult living donor liver transplantation: who is the ideal donor and recipient? J Hepatol (2005) 0.84
N-Acetyl peak in MR spectra of intracranial metastatic mucinous adenocarcinomas. Magn Reson Imaging (2010) 0.83
Liver xenografts for the treatment of acute liver failure: clinical and experimental experience and remaining immunologic barriers. Liver Transpl (2008) 0.82
Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: One- and two-year outcomes. Transplantation (2006) 0.82
Pancreatic transplantation at the University of Pittsburgh. Clin Transpl (2004) 0.81
Pancreas transplantation under alemtuzumab (Campath-1H) and tacrolimus: Correlation between low T-cell responses and infection. Transplantation (2006) 0.81
MR perfusion-weighted imaging may help in differentiating between nonenhancing gliomas and nonneoplastic lesions in the cervicomedullary junction. J Magn Reson Imaging (2011) 0.80
De novo malignancies after intestinal and multivisceral transplantation. Transplantation (2004) 0.79
Infections after living-donor liver transplantation. Surg Infect (Larchmt) (2006) 0.78
PELD allocation and acute liver/graft failure. Liver Transpl (2007) 0.78
Hypophosphatemia and the live liver donor. Transplantation (2005) 0.78
Bloodstream infections in organ transplant recipients receiving alemtuzumab: no evidence of occurrence of organisms typically associated with profound T cell depletion. J Infect (2006) 0.78
Tolerance for organ recipients: a clash of paradigms. Liver Transpl (2006) 0.78
Hepatic arterial anatomy for right liver procurement from living donors. Liver Transpl (2004) 0.77
Comparison of two different techniques of reperfusion in adult orthotopic liver transplantation. Clin Transplant (2006) 0.76
Rapamycin: friend, foe, or misunderstood? Liver Transpl (2003) 0.76
Cold heparinized lactated Ringers with procaine (HeLP) preservation fluid in 266 living donor kidney transplantations. Transplantation (2007) 0.75
Ectoparasite awareness in sheep. Vet Rec (2003) 0.75
Thrombotic and nonthrombotic hepatic artery complications in adults and children following primary liver transplantation with long-term follow-up in 1000 consecutive patients. Transpl Int (2006) 0.75
Liver resection using a saline-linked radiofrequency dissecting sealer for transection of the liver. J Am Coll Surg (2005) 0.75
A case of cervical spinal cord glioblastoma diagnosed with MR diffusion tensor and perfusion imaging. J Neuroimaging (2009) 0.75
Pulmonary actinomycosis in solid organ transplantation. Transplantation (2003) 0.75
In the eye of the beholder: evolving etiologies in acute liver failure. J Clin Gastroenterol (2004) 0.75
Beyond the body surface area vauthey formula to identify the minimal donor volume for right-lobe living-donor liver transplantation. Liver Transpl (2009) 0.75
Alemtuzumab pretreatment and tacrolimus monotherapy in living-donor liver and kidney transplantation. Expert Rev Pharmacoecon Outcomes Res (2007) 0.75